Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases

Inflammation plays a critical role in several diseases such as cancer, gastric, heart and nervous system diseases. Data suggest that the activation of mammalian target of rapamycin (mTOR) pathway in epithelial cells leads to inflammation. Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coe...

Full description

Saved in:
Bibliographic Details
Published in:Inflammopharmacology 2023-02, Vol.31 (1), p.57-75
Main Authors: Lashgari, Naser-Aldin, Roudsari, Nazanin Momeni, Zadeh, Seyed Saeed Tamehri, Momtaz, Saeideh, Abbasifard, Mitra, Reiner, Željko, Abdolghaffari, Amir Hossein, Sahebkar, Amirhossein
Format: Article
Language:English
Subjects:
Allergology
Biomedical and Life Sciences
Biomedicine
Dermatology
Gastroenterology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Immunology
Inflammation - drug therapy
Neurodegenerative Diseases - drug therapy
Pharmacology/Toxicology
Review
Rheumatology
Sirolimus - therapeutic use
TOR Serine-Threonine Kinases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c446t-214f36ea8db85c41c0c6f15be8061b3e308c80cc87a0835339ef6177b93e75c13
cites cdi_FETCH-LOGICAL-c446t-214f36ea8db85c41c0c6f15be8061b3e308c80cc87a0835339ef6177b93e75c13
container_end_page 75
container_issue 1
container_start_page 57
container_title Inflammopharmacology
container_volume 31
creator Lashgari, Naser-Aldin
Roudsari, Nazanin Momeni
Zadeh, Seyed Saeed Tamehri
Momtaz, Saeideh
Abbasifard, Mitra
Reiner, Željko
Abdolghaffari, Amir Hossein
Sahebkar, Amirhossein
description Inflammation plays a critical role in several diseases such as cancer, gastric, heart and nervous system diseases. Data suggest that the activation of mammalian target of rapamycin (mTOR) pathway in epithelial cells leads to inflammation. Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), seem to be able to inhibit the mTOR. Statins are considered to have favorable effects on inflammatory diseases by reducing the complications caused by inflammation and by regulating the inflammatory process and cytokines secretion. This critical review collected data on this topic from clinical, in vivo and in vitro studies published between 1998 and June 2022 in English from databases including PubMed, Google Scholar, Scopus, and Cochrane libraries.
doi_str_mv 10.1007/s10787-022-01077-w
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9792946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36574095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-214f36ea8db85c41c0c6f15be8061b3e308c80cc87a0835339ef6177b93e75c13</originalsourceid><addsrcrecordid>eNp9kdGO1CAUhonRuLOrL-CF4QGsQmmBemFiNuqabOKFek1O6WmHtYUJMDPpg-z7yji60RuvIDn__0HOR8gLzl5zxtSbxJnSqmJ1XbFyVdXxEdnwVuqqlUw_JhvW1W3VyK6-IJcp3THGpJLdU3IhZKsa1rUbcv81Q3Y-0X4O9gddYFlgduBphjhhpmGkEXawrNZ5uoO8PcL6lgLdhZRcPyP14YAzzVssMdxnZ2nKETJOKx1DpM6P84mZQ1xf0RN78uAzBT9Qj_sYBpzQl3J2B6SDSwgJ0zPyZIQ54fPf5xX5_vHDt-ub6vbLp8_X728r2zQyVzVvRiER9NDr1jbcMitH3vaomeS9QMG01cxarYBp0QrR4Si5Un0nULWWiyvy7szd7fsFB4u-_H02u-gWiKsJ4My_E--2ZgoH06mu7hpZAPUZYGNZSMTxocuZOUkyZ0mmSDK_JJljKb38-9WHyh8rJSDOgVRGfsJo7sI--rKJ_2F_AlqKo-I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases</title><source>Springer Nature</source><creator>Lashgari, Naser-Aldin ; Roudsari, Nazanin Momeni ; Zadeh, Seyed Saeed Tamehri ; Momtaz, Saeideh ; Abbasifard, Mitra ; Reiner, Željko ; Abdolghaffari, Amir Hossein ; Sahebkar, Amirhossein</creator><creatorcontrib>Lashgari, Naser-Aldin ; Roudsari, Nazanin Momeni ; Zadeh, Seyed Saeed Tamehri ; Momtaz, Saeideh ; Abbasifard, Mitra ; Reiner, Željko ; Abdolghaffari, Amir Hossein ; Sahebkar, Amirhossein</creatorcontrib><description>Inflammation plays a critical role in several diseases such as cancer, gastric, heart and nervous system diseases. Data suggest that the activation of mammalian target of rapamycin (mTOR) pathway in epithelial cells leads to inflammation. Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), seem to be able to inhibit the mTOR. Statins are considered to have favorable effects on inflammatory diseases by reducing the complications caused by inflammation and by regulating the inflammatory process and cytokines secretion. This critical review collected data on this topic from clinical, in vivo and in vitro studies published between 1998 and June 2022 in English from databases including PubMed, Google Scholar, Scopus, and Cochrane libraries.</description><identifier>ISSN: 0925-4692</identifier><identifier>EISSN: 1568-5608</identifier><identifier>DOI: 10.1007/s10787-022-01077-w</identifier><identifier>PMID: 36574095</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Allergology ; Biomedical and Life Sciences ; Biomedicine ; Dermatology ; Gastroenterology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Immunology ; Inflammation - drug therapy ; Neurodegenerative Diseases - drug therapy ; Pharmacology/Toxicology ; Review ; Rheumatology ; Sirolimus - therapeutic use ; TOR Serine-Threonine Kinases</subject><ispartof>Inflammopharmacology, 2023-02, Vol.31 (1), p.57-75</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-214f36ea8db85c41c0c6f15be8061b3e308c80cc87a0835339ef6177b93e75c13</citedby><cites>FETCH-LOGICAL-c446t-214f36ea8db85c41c0c6f15be8061b3e308c80cc87a0835339ef6177b93e75c13</cites><orcidid>0000-0002-8656-1444</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36574095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lashgari, Naser-Aldin</creatorcontrib><creatorcontrib>Roudsari, Nazanin Momeni</creatorcontrib><creatorcontrib>Zadeh, Seyed Saeed Tamehri</creatorcontrib><creatorcontrib>Momtaz, Saeideh</creatorcontrib><creatorcontrib>Abbasifard, Mitra</creatorcontrib><creatorcontrib>Reiner, Željko</creatorcontrib><creatorcontrib>Abdolghaffari, Amir Hossein</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><title>Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases</title><title>Inflammopharmacology</title><addtitle>Inflammopharmacol</addtitle><addtitle>Inflammopharmacology</addtitle><description>Inflammation plays a critical role in several diseases such as cancer, gastric, heart and nervous system diseases. Data suggest that the activation of mammalian target of rapamycin (mTOR) pathway in epithelial cells leads to inflammation. Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), seem to be able to inhibit the mTOR. Statins are considered to have favorable effects on inflammatory diseases by reducing the complications caused by inflammation and by regulating the inflammatory process and cytokines secretion. This critical review collected data on this topic from clinical, in vivo and in vitro studies published between 1998 and June 2022 in English from databases including PubMed, Google Scholar, Scopus, and Cochrane libraries.</description><subject>Allergology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Dermatology</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Immunology</subject><subject>Inflammation - drug therapy</subject><subject>Neurodegenerative Diseases - drug therapy</subject><subject>Pharmacology/Toxicology</subject><subject>Review</subject><subject>Rheumatology</subject><subject>Sirolimus - therapeutic use</subject><subject>TOR Serine-Threonine Kinases</subject><issn>0925-4692</issn><issn>1568-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kdGO1CAUhonRuLOrL-CF4QGsQmmBemFiNuqabOKFek1O6WmHtYUJMDPpg-z7yji60RuvIDn__0HOR8gLzl5zxtSbxJnSqmJ1XbFyVdXxEdnwVuqqlUw_JhvW1W3VyK6-IJcp3THGpJLdU3IhZKsa1rUbcv81Q3Y-0X4O9gddYFlgduBphjhhpmGkEXawrNZ5uoO8PcL6lgLdhZRcPyP14YAzzVssMdxnZ2nKETJOKx1DpM6P84mZQ1xf0RN78uAzBT9Qj_sYBpzQl3J2B6SDSwgJ0zPyZIQ54fPf5xX5_vHDt-ub6vbLp8_X728r2zQyVzVvRiER9NDr1jbcMitH3vaomeS9QMG01cxarYBp0QrR4Si5Un0nULWWiyvy7szd7fsFB4u-_H02u-gWiKsJ4My_E--2ZgoH06mu7hpZAPUZYGNZSMTxocuZOUkyZ0mmSDK_JJljKb38-9WHyh8rJSDOgVRGfsJo7sI--rKJ_2F_AlqKo-I</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Lashgari, Naser-Aldin</creator><creator>Roudsari, Nazanin Momeni</creator><creator>Zadeh, Seyed Saeed Tamehri</creator><creator>Momtaz, Saeideh</creator><creator>Abbasifard, Mitra</creator><creator>Reiner, Željko</creator><creator>Abdolghaffari, Amir Hossein</creator><creator>Sahebkar, Amirhossein</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid></search><sort><creationdate>20230201</creationdate><title>Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases</title><author>Lashgari, Naser-Aldin ; Roudsari, Nazanin Momeni ; Zadeh, Seyed Saeed Tamehri ; Momtaz, Saeideh ; Abbasifard, Mitra ; Reiner, Željko ; Abdolghaffari, Amir Hossein ; Sahebkar, Amirhossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-214f36ea8db85c41c0c6f15be8061b3e308c80cc87a0835339ef6177b93e75c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allergology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Dermatology</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Immunology</topic><topic>Inflammation - drug therapy</topic><topic>Neurodegenerative Diseases - drug therapy</topic><topic>Pharmacology/Toxicology</topic><topic>Review</topic><topic>Rheumatology</topic><topic>Sirolimus - therapeutic use</topic><topic>TOR Serine-Threonine Kinases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lashgari, Naser-Aldin</creatorcontrib><creatorcontrib>Roudsari, Nazanin Momeni</creatorcontrib><creatorcontrib>Zadeh, Seyed Saeed Tamehri</creatorcontrib><creatorcontrib>Momtaz, Saeideh</creatorcontrib><creatorcontrib>Abbasifard, Mitra</creatorcontrib><creatorcontrib>Reiner, Željko</creatorcontrib><creatorcontrib>Abdolghaffari, Amir Hossein</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Inflammopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lashgari, Naser-Aldin</au><au>Roudsari, Nazanin Momeni</au><au>Zadeh, Seyed Saeed Tamehri</au><au>Momtaz, Saeideh</au><au>Abbasifard, Mitra</au><au>Reiner, Željko</au><au>Abdolghaffari, Amir Hossein</au><au>Sahebkar, Amirhossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases</atitle><jtitle>Inflammopharmacology</jtitle><stitle>Inflammopharmacol</stitle><addtitle>Inflammopharmacology</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>31</volume><issue>1</issue><spage>57</spage><epage>75</epage><pages>57-75</pages><issn>0925-4692</issn><eissn>1568-5608</eissn><abstract>Inflammation plays a critical role in several diseases such as cancer, gastric, heart and nervous system diseases. Data suggest that the activation of mammalian target of rapamycin (mTOR) pathway in epithelial cells leads to inflammation. Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), seem to be able to inhibit the mTOR. Statins are considered to have favorable effects on inflammatory diseases by reducing the complications caused by inflammation and by regulating the inflammatory process and cytokines secretion. This critical review collected data on this topic from clinical, in vivo and in vitro studies published between 1998 and June 2022 in English from databases including PubMed, Google Scholar, Scopus, and Cochrane libraries.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36574095</pmid><doi>10.1007/s10787-022-01077-w</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0925-4692
ispartof Inflammopharmacology, 2023-02, Vol.31 (1), p.57-75
issn 0925-4692
1568-5608
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9792946
source Springer Nature
subjects Allergology
Biomedical and Life Sciences
Biomedicine
Dermatology
Gastroenterology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Immunology
Inflammation - drug therapy
Neurodegenerative Diseases - drug therapy
Pharmacology/Toxicology
Review
Rheumatology
Sirolimus - therapeutic use
TOR Serine-Threonine Kinases
title Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A54%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statins%20block%20mammalian%20target%20of%20rapamycin%20pathway:%20a%20possible%20novel%20therapeutic%20strategy%20for%20inflammatory,%20malignant%20and%20neurodegenerative%20diseases&rft.jtitle=Inflammopharmacology&rft.au=Lashgari,%20Naser-Aldin&rft.date=2023-02-01&rft.volume=31&rft.issue=1&rft.spage=57&rft.epage=75&rft.pages=57-75&rft.issn=0925-4692&rft.eissn=1568-5608&rft_id=info:doi/10.1007/s10787-022-01077-w&rft_dat=%3Cpubmed_cross%3E36574095%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-214f36ea8db85c41c0c6f15be8061b3e308c80cc87a0835339ef6177b93e75c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/36574095&rfr_iscdi=true